Correlation Between SUA and Prognosis in CHF Patients After Revascularization

Background: To explore the correlation between serum uric acid (SUA) and prognosis in patients with chronic heart failure (CHF) after revascularization. Methods: A total of 126 patients with CHF undergoing revascularization [coronary artery intervention (PCI) or coronary artery bypass grafting (CABG)] in the hospital were enrolled as CHF group between December 2021 and October 2022, while 126 healthy controls during the same period were enrolled as healthy control group. The levels of SUA, inflammatory factors and cardiac function in the two groups were detected. The correlation between SUA level and inflammatory factors, cardiac function levels was analyzed. All patients in CHF group were followed up for 6 months to observe prognosis. The differences in the above indexes among patients with different prognosis were compared. The risk factors of prognosis were analyzed by multivariate Logistic regression analysis, and their predictive value for prognosis was evaluated by ROC curves analysis. Results: SUA, IL-6, TNF-α, NT-proBNP and LVEDD in CHF group were higher than those in healthy control group, while LVEF was lower than that in healthy control group (P<0.05). Among the 126 patients within 6 months after surgery, there were 24 cases (19.05%) with adverse cardiac events (poor prognosis). SUA, IL-6, TNF-α, NT-proBNP and LVEDD in patients with poor prognosis were higher than those with good prognosis, while LVEF was lower than that with good prognosis (P<0.05). SUA level was positively correlated with IL-6, TNF-α, NT-proBNP and LVEDD (r=0.283, 0.292, 0.322, 0.355, P<0.05), while negatively correlated with LVEF (r=-0.368, P<0.05). High level of SUA and low LVEF were independent risk factors of prognosis (OR=1.486, 0.678, P<0.05). Both SUA and LVEF were of prognostic value (AUC=0.805, 0.809, P<0.05). Conclusion: SUA level is significantly increased in CHF patients, which is an independent risk factor of poor prognosis in CHF patients after revascularization, with high prognostic value.

[1]  Jiayu Zhao,et al.  A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients , 2022, Frontiers in Cardiovascular Medicine.

[2]  G. Filippatos,et al.  Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial , 2022, European heart journal.

[3]  Li Liu,et al.  Preclinical study of Shen Qi Li Xin formula in improving the development of chronic heart failure. , 2022, Histology and Histopathology.

[4]  Seyedeh Leila Zonnoor,et al.  Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions , 2022, Cureus.

[5]  G. Targher,et al.  Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. , 2022, International journal of cardiology.

[6]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[7]  Caroline A. Lee,et al.  In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters , 2021, The Journal of Pharmacology and Experimental Therapeutics.

[8]  Jin Jin,et al.  A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair , 2021, Signal Transduction and Targeted Therapy.

[9]  F. Leclercq,et al.  Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score , 2021, Clinical Chemistry and Laboratory Medicine.

[10]  C. Wojciechowska,et al.  Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure , 2019, Oxidative medicine and cellular longevity.

[11]  J. Vítovec,et al.  Pathophysiology, causes and epidemiology of chronic heart failure. , 2018, Vnitrni lekarstvi.

[12]  J. Shu,et al.  [Relationship between hyperuricemia and prognosis in patients with heart failure of coronary heart disease after revascularization]. , 2018, Zhonghua yi xue za zhi.

[13]  T. Doenst,et al.  Cardiac surgery 2015 reviewed , 2016, Clinical Research in Cardiology.

[14]  M. Mori,et al.  Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. , 2012, Thyroid : official journal of the American Thyroid Association.

[15]  L. Tan,et al.  How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure? , 2005, American heart journal.